In early March 2020, Biotyx representatives and American expert Dr. Daniel McLennan went to Kuala Lumpur, Malaysia to conduct academic exchanges friendly with Dr. Mazeni Alwi and Dr. Koh Ghee Tiong, well-known in the field of cardiac intervention. The topic focuses on the clinical application experience of the IBS Angel™ iron bioabsorbable scaffold independently developed by Biotyx.
In early March 2020, Biotyx representatives and American expert Dr. Daniel McLennan went to Kuala Lumpur, Malaysia to conduct academic exchanges friendly with Dr. Mazeni Alwi and Dr. Koh Ghee Tiong, well-known in the field of cardiac intervention. The topic focuses on the clinical application experience of the IBS Angel™ iron bioabsorbable scaffold independently developed by Biotyx.
(Video: Highlights of academic seminars)
The team of American expert Dr. Daniel McLennan first visited the National Hospital in Kuala Lumpur, Malaysia. The team of Malaysian expert Dr. Koh Ghee Tiong showed American experts their PDA scaffold implantation using IBS Angel™ iron bioabsorbable scaffold. The entire operation of Dr. Koh Ghee Tiong took a short time, the process was very smooth, and achieved great success, which reserved a survival time for the next scheduled cardiac surgery for the child.
Malaysian Kuala Lumpur National Hospital Station
Malaysian Kuala Lumpur National Hospital Station
In the postoperative communication, Dr. Koh Ghee Tiong shared his clinical experience and challenging cases of using IBS Angel™ iron bioabsorbable scaffolds with American experts. The discussion atmosphere was warm, and Dr. Daniel McLennan expressed with excitement that the IBS Angel™ iron bioabsorbable scaffold filled the gap in the world and was a long-awaited children's absorbable scaffold product.
(Dr. Koh Ghee Tiong introduces IBS Angel™ iron bioabsorbable scaffold to Dr. Daniel McLennan from the United States)
Picture: American expert team took a group photo with Dr. Koh Ghee Tiong and Biotyx representatives
Malaysian National Heart Institute Station
The National Heart Institute of Malaysia is the world’s first human clinical trial center for the IBS Angel™ iron bioabsorbable scaffold. As the main clinical investigator of the IBS Angel™ iron bioabsorbable scaffold, Dr. Mazeni Alwi introduced the IBS Angel™ to American experts the results of the clinical trial completed by the iron bioabsorbable scaffold at its center. The current research results show that the immediate success rate of the operation is 100%, and the preliminary results are positive.
(Picture: Dr. Mazeni Alwi introduces the clinical trial results of IBS Angel™ iron bioabsorbable scaffold to American experts.)
Dr. Mazeni Alwi said that the IBS Angel™ iron bioabsorbable scaffold has many advantages and is very suitable for children with complicated arterial catheter-dependent congenital heart disease and children with congenital pulmonary vascular disease. The small size of its delivery system profile makes it suitable for neonates and infants; its absorbable characteristics make it unnecessary to remove the scaffold during subsequent cardiac surgery, which reduce damage to the pulmonary artery, facilitate the ligation of the arterial catheter, and reduce complications after cardiac surgery.
After the clinical academic exchange meeting, Dr. Wenjiao Lin and Dr. Li Qin from Biotyx and Dr. Mazeni Alwi and Dr. Daniel McLennan discussed the potential indications of IBS Angel™ iron bioabsorbable scaffold products, product design requirements and product strategy for entering the North American market. Both doctors said that the IBS Angel™ iron bioabsorbable scaffold can also be applied to other cardiopulmonary vessels besides arterial catheters. The IBS Angel™ iron bioabsorbable scaffold has great advantages for infants and children, and the children benefit greatly.
Dr. Daniel McLennan said he is looking forward to the IBS Angel™ iron bioabsorbable scaffold entering the North American market. Biotyx plans to apply for the Humanitarian Use Device (HUD) for the IBS Angel™ iron bioabsorbable scaffold, and seeks to enter the North American market through this way, which will bring children in North America great benefits.
After the exchange, American experts all expressed that they benefited a lot from learning during the operation and communication, and expressed high praise and expectation for Biotyx's innovative products and advanced technology. Dr. Daniel McLennan praised the unique characteristics of the IBS Angel™ iron bioabsorbable scaffold, and sighed that the rapid progress of China's medical technology level can regain hope for more children with complex congenital diseases in urgent need of treatment.
